CATALYST is a collaborative phase II adaptive platform trial set up in response to the Coronavirus Disease 2019 (COVID-19) pandemic. We work with intensive care, respiratory and inflammatory researchers across the UK to rapidly trial new treatments for UK patients hospitalised with severe COVID-19.
We are able to deliver and evolve CATALYST at pace due to the large and excellent network of partners, including NIHR BRCs at Birmingham, Oxford and UCL, Birmingham Acute Care Research, the NIHR Clinical Research Network, UKRI MRC and our industry partners at Celltrion and Izana.
Find out more about the trial and its background.
Find out more about the trial background, design, and sites.
Access information for hospitals and download current trial documentation.
Also in 'CATALYST'